Discover how the HEK293-derived Pro10™ cell line accelerates AAV vector production. This whitepaper explores a scalable, animal component-free platform that reduces process development time and costs, meeting growing clinical and commercial demands for gene therapies.
Resources
February 06, 2023
White paper: A proprietary mammalian suspension technology for scalable rAAV production: The Pro10™ cell line
Explore more

News
Viralgen collaborates with Trogenix to advance AAV gene therapy for glioblastoma
Viralgen accelerates clinical development process: scaling manufacturing and completing GMP production of Trogenix’s AAV gene therapy in under 12 months. San Sebastián, Spain, 6 May 2025 – Viralgen, a leading contract development and manufacturing...
READ MORE
May 06, 2025

Insights
All In on Rare Disease Day 2025: Viralgen Event Highlights Critical Collaborations to Advance Successful Gene Therapies
“Understand that we are the only ones capable of doing this task, because we’ve cared from the very beginning, because we have the capabilities, and because we can bring all the pieces together. So don't underestimate the power of what you do in the...
READ MORE
March 19, 2025

News
Viralgen and CTNNB1 Foundation partner to manufacture a new gene therapy for CTNNB1 Syndrome
Patients with CTNNB1 Syndrome will benefit from this joint effort to develop and manufacture a new AAV investigational gene therapy, which aims to restore gene function and may improve quality of life. San Sebastián, Spain and Ljubljana, Slovenia,...
READ MORE
February 05, 2025